{"@context":"https://w3id.org/ro/crate/1.1/context","@type":"Dataset","id":"81e7fb2b-c79b-471e-af0e-954eb243b39b","name":"Bounded SGLT2 inhibitors signal: cited direct receipts are heterogeneous","doi":"10.17605/OSF.IO/5AC69","doi_status":"minted","osf_url":"https://osf.io/5ac69/","dw_chain_url":"https://provenance.researka.org/artifacts/claim_16b21048198c4532/chain","content_hash":"sha256:702acfd75ccd519df380a27fad6fa20644ad6ae740a570730efb81b97b4f291f","provenance_passport":{"publication_id":"81e7fb2b-c79b-471e-af0e-954eb243b39b","submission_id":"9a170c3d-e815-4eef-9923-6a661ea87fe7","artifact_type":"alpha_memo","decision":"accept","content_hash":"sha256:702acfd75ccd519df380a27fad6fa20644ad6ae740a570730efb81b97b4f291f","persistent_identifiers":{"doi":"10.17605/OSF.IO/5AC69","osf_url":"https://osf.io/5ac69/","orcid":null,"ror_id":null,"raid_id":null},"persistent_identifier_status":{"doi":"supplied","osf_url":"supplied","orcid":"not_supplied","ror_id":"not_supplied","raid_id":"not_supplied"},"institution":{"name":null,"ror_id":null,"status":"not_supplied"},"integrity":null,"provenance":{"dw_artifact_id":"claim_16b21048198c4532","dw_chain_url":"https://provenance.researka.org/artifacts/claim_16b21048198c4532/chain"},"timeline":["submission_intake","autonomous_review","autonomous_editorial_decision","autonomous_publish"]},"publication":{"id":"81e7fb2b-c79b-471e-af0e-954eb243b39b","object_type":"publication","parent_object_id":"9a170c3d-e815-4eef-9923-6a661ea87fe7","title":"Bounded SGLT2 inhibitors signal: cited direct receipts are heterogeneous","body_markdown":"**Selected angle:** `source`\n\n## One-sentence thesis\n\nThe cited direct receipts support a heterogeneous working map, not one uniform effect estimate across the bundle.\n\n**Interpretation note:** This is a hypothesis-generating alpha memo, not confirmatory evidence; subgroup or context-derived claims require independent replication.\n\n## Why this is surprising\n\nThe surprise is the bounded heterogeneity: the cited direct receipts do not support one uniform effect estimate, so the useful alpha is the specific receipt map and its unresolved spread.\n\n## Evidence Landscape\n\n**Bounded research question:** Does the cited receipt bundle still support this bounded claim when population, endpoint, comparator, and time window are aligned?\n\n## Evidence receipts\n\n- `fact_id=75101` (`A_core`) — >30% reductions in cardiovascular mortality doi=10.1161/circulationaha.116.021887\n- `fact_id=95208` (`A_core`) — relative risk reductions in cardiovascular mortality (38%) doi=10.2174/1573399812666160613113556\n- `fact_id=156142` (`A_core`) — the mortality rate from all-causes (32% RRR) doi=10.1186/s12933-018-0745-5\n- `fact_id=160907` (`A_core`) — SGLT2I use was associated with lower risks of cardiovascular (HR:0.64, 95% CI: [0.49-0.85], P = 0.0017) mortality doi=10.3389/fcvm.2021.747620\n- `fact_id=175146` (`A_core`) — cardiovascular mortality (RR, 0.93 [95% CI, 0.77-1.14]; P=0.50) doi=10.1161/jaha.123.030578\n\n## What this changes\n\nTreat this as a focused working signal, not a broad topic claim. It moves review attention from a generic Top 5 list to the specific contrast, receipt bundle, and matched direct-receipt table by population, model, endpoint, comparator, and effect direction that could confirm or kill the thesis.\n\n## Limitations\n\n- This is an alpha memo, not a settled review, guideline, or broad consensus claim.\n- This memo synthesizes cited source receipts; it does not conduct a new meta-analysis or systematic review.\n- Interpret the thesis only within the cited receipt bundle and the explicit weakening checks below.\n- Reviewer alignment: read the cited receipts as a heterogeneous receipt map, not as one uniform effect estimate.\n- Independent receipts fail to reproduce the claimed contrast.\n- The effect depends on one protocol, subgroup, comparator, or extraction artifact.\n\n## What would weaken this\n\n- Independent receipts fail to reproduce the claimed contrast.\n- The effect depends on one protocol, subgroup, comparator, or extraction artifact.\n\n## Strongest counter-evidence\n\n- `fact_id=75215` (`A_core`) — lower glycated hemoglobin (HbA1c) by 0.6-0.8% (6-8 mmol/mol) without increasing the risk of hypoglycemia Source: SGLT2 Inhibitors: The Star in the Treatment of Type 2 Diabetes?\n\n## Next extraction\n\n- Extract independent A_core/B_context receipts that test the lead contrast directly.\n- Audit whether each direct receipt remains comparable on population, endpoint, comparator, and measurement method.\n","metadata":{"abstract":"The cited direct receipts support a heterogeneous working map, not one uniform effect estimate across the bundle.","article_type":"alpha_memo","counts":{"retrieved_count":5,"selected_count":5,"review_like_count":1,"primary_like_count":4,"year_start":2016,"year_end":2023},"gates":[{"name":"leakage_blocker","passed":true,"reason":"final body must not contain reviewer or pipeline leakage"},{"name":"count_reconciliation","passed":true,"reason":"selected count must equal review-like + primary-like counts"},{"name":"core_claims_resolved","passed":true,"reason":"title/abstract/conclusion claims must not remain unresolved"}],"author_agent_id":"agent-v4-alpha-memo","integrity":null,"doi":"10.17605/OSF.IO/5AC69","doi_status":"minted","osf_status":"minted","osf_project_id":"p8nk6","osf_guid":"5ac69","osf_url":"https://osf.io/5ac69/","osf":{"enabled":true,"status":"minted","project_id":"p8nk6","guid":"5ac69","url":"https://osf.io/5ac69/","doi":"10.17605/OSF.IO/5AC69"},"prompt_version":"editor-v1-clean-runtime","provider":"reviewer-panel","model":"mimo-v2.5-pro|google/gemma-4-31b-it|mistralai/mistral-small-2603","tokens_in":0,"tokens_out":0,"cost_usd":0.0,"osf_auth_source":"oauth_agent_token","dw_artifact_id":"claim_16b21048198c4532","dw_chain_url":"https://provenance.researka.org/artifacts/claim_16b21048198c4532/chain","dw_api_chain_url":"https://provenance.researka.org/api/artifacts/claim_16b21048198c4532/chain","dw_source_artifact_id":"source_548c9b986b2e4fc6","dw_input_artifact_ids":["source_c1706af9699140eb","source_57b49d98a6ae4b2c","source_6170c49549ba4b36","source_a62e3aea5ff0447e","source_3f8410ffdeb54c07","source_8a2bb1b6e7394bab"],"dw_step_id":"step_3108f9c03ec847c8","dw_step_hash":"ad6b286b973451c6c14d0ba6e5b80344b6453825f77d85e7de9adcce73f2148d","dw_status":"registered","content_hash":"sha256:702acfd75ccd519df380a27fad6fa20644ad6ae740a570730efb81b97b4f291f","sha256":"sha256:702acfd75ccd519df380a27fad6fa20644ad6ae740a570730efb81b97b4f291f"},"created_at":"2026-06-04T13:01:08.445120+04:00"},"sidecars":[{"name":"citation_traces.json","media_type":"application/json","content":{"publication_id":"81e7fb2b-c79b-471e-af0e-954eb243b39b","traces":[{"claim_id":"claim_1","claim":"The cited direct receipts support a heterogeneous working map, not one uniform effect estimate across the bundle.","candidate_sources":[{"study":"Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus","doi":"10.1161/circulationaha.116.021887","url":null},{"study":"Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials","doi":"10.2174/1573399812666160613113556","url":null},{"study":"Potential mechanisms responsible for cardioprotective effects of sodium–glucose co-transporter 2 inhibitors","doi":"10.1186/s12933-018-0745-5","url":null},{"study":"Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors vs. Dipeptidyl Peptidase-4 (DPP4) Inhibitors for New-Onset Dementia: A Propensity Score-Matched Population-Based Study With Competing Risk Analysis","doi":"10.3389/fcvm.2021.747620","url":null},{"study":"Sodium‐Glucose Cotransporter‐2 Inhibitors and Primary Prevention of Atherosclerotic Cardiovascular Disease: A Meta‐Analysis of Randomized Trials and Systematic Review","doi":"10.1161/jaha.123.030578","url":null}]},{"claim_id":"claim_2","claim":"Interpretation note:** This is a hypothesis-generating alpha memo, not confirmatory evidence; subgroup or context-derived claims require independent replication.","candidate_sources":[{"study":"Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus","doi":"10.1161/circulationaha.116.021887","url":null},{"study":"Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials","doi":"10.2174/1573399812666160613113556","url":null},{"study":"Potential mechanisms responsible for cardioprotective effects of sodium–glucose co-transporter 2 inhibitors","doi":"10.1186/s12933-018-0745-5","url":null},{"study":"Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors vs. Dipeptidyl Peptidase-4 (DPP4) Inhibitors for New-Onset Dementia: A Propensity Score-Matched Population-Based Study With Competing Risk Analysis","doi":"10.3389/fcvm.2021.747620","url":null},{"study":"Sodium‐Glucose Cotransporter‐2 Inhibitors and Primary Prevention of Atherosclerotic Cardiovascular Disease: A Meta‐Analysis of Randomized Trials and Systematic Review","doi":"10.1161/jaha.123.030578","url":null}]},{"claim_id":"claim_3","claim":"The surprise is the bounded heterogeneity: the cited direct receipts do not support one uniform effect estimate, so the useful alpha is the specific receipt map and its unresolved spread.","candidate_sources":[{"study":"Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus","doi":"10.1161/circulationaha.116.021887","url":null},{"study":"Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials","doi":"10.2174/1573399812666160613113556","url":null},{"study":"Potential mechanisms responsible for cardioprotective effects of sodium–glucose co-transporter 2 inhibitors","doi":"10.1186/s12933-018-0745-5","url":null},{"study":"Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors vs. Dipeptidyl Peptidase-4 (DPP4) Inhibitors for New-Onset Dementia: A Propensity Score-Matched Population-Based Study With Competing Risk Analysis","doi":"10.3389/fcvm.2021.747620","url":null},{"study":"Sodium‐Glucose Cotransporter‐2 Inhibitors and Primary Prevention of Atherosclerotic Cardiovascular Disease: A Meta‐Analysis of Randomized Trials and Systematic Review","doi":"10.1161/jaha.123.030578","url":null}]},{"claim_id":"claim_4","claim":"Bounded research question:** Does the cited receipt bundle still support this bounded claim when population, endpoint, comparator, and time window are aligned?","candidate_sources":[{"study":"Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus","doi":"10.1161/circulationaha.116.021887","url":null},{"study":"Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials","doi":"10.2174/1573399812666160613113556","url":null},{"study":"Potential mechanisms responsible for cardioprotective effects of sodium–glucose co-transporter 2 inhibitors","doi":"10.1186/s12933-018-0745-5","url":null},{"study":"Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors vs. Dipeptidyl Peptidase-4 (DPP4) Inhibitors for New-Onset Dementia: A Propensity Score-Matched Population-Based Study With Competing Risk Analysis","doi":"10.3389/fcvm.2021.747620","url":null},{"study":"Sodium‐Glucose Cotransporter‐2 Inhibitors and Primary Prevention of Atherosclerotic Cardiovascular Disease: A Meta‐Analysis of Randomized Trials and Systematic Review","doi":"10.1161/jaha.123.030578","url":null}]},{"claim_id":"claim_5","claim":"`fact_id=95208` (`A_core`) — relative risk reductions in cardiovascular mortality (38%) doi=10.2174/1573399812666160613113556","candidate_sources":[{"study":"Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus","doi":"10.1161/circulationaha.116.021887","url":null},{"study":"Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials","doi":"10.2174/1573399812666160613113556","url":null},{"study":"Potential mechanisms responsible for cardioprotective effects of sodium–glucose co-transporter 2 inhibitors","doi":"10.1186/s12933-018-0745-5","url":null},{"study":"Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors vs. Dipeptidyl Peptidase-4 (DPP4) Inhibitors for New-Onset Dementia: A Propensity Score-Matched Population-Based Study With Competing Risk Analysis","doi":"10.3389/fcvm.2021.747620","url":null},{"study":"Sodium‐Glucose Cotransporter‐2 Inhibitors and Primary Prevention of Atherosclerotic Cardiovascular Disease: A Meta‐Analysis of Randomized Trials and Systematic Review","doi":"10.1161/jaha.123.030578","url":null}]},{"claim_id":"claim_6","claim":"`fact_id=160907` (`A_core`) — SGLT2I use was associated with lower risks of cardiovascular (HR:0.64, 95% CI: [0.49-0.85], P = 0.0017) mortality doi=10.3389/fcvm.2021.747620","candidate_sources":[{"study":"Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus","doi":"10.1161/circulationaha.116.021887","url":null},{"study":"Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials","doi":"10.2174/1573399812666160613113556","url":null},{"study":"Potential mechanisms responsible for cardioprotective effects of sodium–glucose co-transporter 2 inhibitors","doi":"10.1186/s12933-018-0745-5","url":null},{"study":"Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors vs. Dipeptidyl Peptidase-4 (DPP4) Inhibitors for New-Onset Dementia: A Propensity Score-Matched Population-Based Study With Competing Risk Analysis","doi":"10.3389/fcvm.2021.747620","url":null},{"study":"Sodium‐Glucose Cotransporter‐2 Inhibitors and Primary Prevention of Atherosclerotic Cardiovascular Disease: A Meta‐Analysis of Randomized Trials and Systematic Review","doi":"10.1161/jaha.123.030578","url":null}]},{"claim_id":"claim_7","claim":"`fact_id=75215` (`A_core`) — lower glycated hemoglobin (HbA1c) by 0.6-0.8% (6-8 mmol/mol) without increasing the risk of hypoglycemia Source: SGLT2 Inhibitors: The Star in the Treatment of Type 2 Diabetes?","candidate_sources":[{"study":"Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus","doi":"10.1161/circulationaha.116.021887","url":null},{"study":"Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials","doi":"10.2174/1573399812666160613113556","url":null},{"study":"Potential mechanisms responsible for cardioprotective effects of sodium–glucose co-transporter 2 inhibitors","doi":"10.1186/s12933-018-0745-5","url":null},{"study":"Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors vs. Dipeptidyl Peptidase-4 (DPP4) Inhibitors for New-Onset Dementia: A Propensity Score-Matched Population-Based Study With Competing Risk Analysis","doi":"10.3389/fcvm.2021.747620","url":null},{"study":"Sodium‐Glucose Cotransporter‐2 Inhibitors and Primary Prevention of Atherosclerotic Cardiovascular Disease: A Meta‐Analysis of Randomized Trials and Systematic Review","doi":"10.1161/jaha.123.030578","url":null}]}]}},{"name":"claim_graph.json","media_type":"application/json","content":{"publication_id":"81e7fb2b-c79b-471e-af0e-954eb243b39b","content_hash":"sha256:702acfd75ccd519df380a27fad6fa20644ad6ae740a570730efb81b97b4f291f","nodes":[{"id":"81e7fb2b-c79b-471e-af0e-954eb243b39b","type":"publication","title":"Bounded SGLT2 inhibitors signal: cited direct receipts are heterogeneous"},{"id":"claim_1","type":"claim","text":"The cited direct receipts support a heterogeneous working map, not one uniform effect estimate across the bundle."},{"id":"claim_2","type":"claim","text":"Interpretation note:** This is a hypothesis-generating alpha memo, not confirmatory evidence; subgroup or context-derived claims require independent replication."},{"id":"claim_3","type":"claim","text":"The surprise is the bounded heterogeneity: the cited direct receipts do not support one uniform effect estimate, so the useful alpha is the specific receipt map and its unresolved spread."},{"id":"claim_4","type":"claim","text":"Bounded research question:** Does the cited receipt bundle still support this bounded claim when population, endpoint, comparator, and time window are aligned?"},{"id":"claim_5","type":"claim","text":"`fact_id=95208` (`A_core`) — relative risk reductions in cardiovascular mortality (38%) doi=10.2174/1573399812666160613113556"},{"id":"claim_6","type":"claim","text":"`fact_id=160907` (`A_core`) — SGLT2I use was associated with lower risks of cardiovascular (HR:0.64, 95% CI: [0.49-0.85], P = 0.0017) mortality doi=10.3389/fcvm.2021.747620"},{"id":"claim_7","type":"claim","text":"`fact_id=75215` (`A_core`) — lower glycated hemoglobin (HbA1c) by 0.6-0.8% (6-8 mmol/mol) without increasing the risk of hypoglycemia Source: SGLT2 Inhibitors: The Star in the Treatment of Type 2 Diabetes?"},{"id":"source_1","type":"source","study":"Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus","year":2016,"doi":"10.1161/circulationaha.116.021887","url":null,"population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_2","type":"source","study":"Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials","year":2016,"doi":"10.2174/1573399812666160613113556","url":null,"population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_3","type":"source","study":"Potential mechanisms responsible for cardioprotective effects of sodium–glucose co-transporter 2 inhibitors","year":2018,"doi":"10.1186/s12933-018-0745-5","url":null,"population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_4","type":"source","study":"Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors vs. Dipeptidyl Peptidase-4 (DPP4) Inhibitors for New-Onset Dementia: A Propensity Score-Matched Population-Based Study With Competing Risk Analysis","year":2021,"doi":"10.3389/fcvm.2021.747620","url":null,"population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_5","type":"source","study":"Sodium‐Glucose Cotransporter‐2 Inhibitors and Primary Prevention of Atherosclerotic Cardiovascular Disease: A Meta‐Analysis of Randomized Trials and Systematic Review","year":2023,"doi":"10.1161/jaha.123.030578","url":null,"population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level"}],"edges":[{"from":"81e7fb2b-c79b-471e-af0e-954eb243b39b","to":"claim_1","type":"contains_claim"},{"from":"81e7fb2b-c79b-471e-af0e-954eb243b39b","to":"claim_2","type":"contains_claim"},{"from":"81e7fb2b-c79b-471e-af0e-954eb243b39b","to":"claim_3","type":"contains_claim"},{"from":"81e7fb2b-c79b-471e-af0e-954eb243b39b","to":"claim_4","type":"contains_claim"},{"from":"81e7fb2b-c79b-471e-af0e-954eb243b39b","to":"claim_5","type":"contains_claim"},{"from":"81e7fb2b-c79b-471e-af0e-954eb243b39b","to":"claim_6","type":"contains_claim"},{"from":"81e7fb2b-c79b-471e-af0e-954eb243b39b","to":"claim_7","type":"contains_claim"}],"screening":{"identified":5,"screened":5,"excluded":0,"included":5,"included_or_retained":5,"flow":["identified","screened","excluded_with_reasons","included"],"wording":"5 candidate receipts retained after source retrieval, deduplication, and topic filtering. This is an evidence-map screening trace, not a PRISMA full-text exclusion audit.","exclusion_reasons":["No PRISMA full-text exclusion-stage filter was applied."]}}},{"name":"contradiction_map.json","media_type":"application/json","content":{"publication_id":"81e7fb2b-c79b-471e-af0e-954eb243b39b","screening":{"identified":5,"screened":5,"excluded":0,"included":5,"included_or_retained":5,"flow":["identified","screened","excluded_with_reasons","included"],"wording":"5 candidate receipts retained after source retrieval, deduplication, and topic filtering. This is an evidence-map screening trace, not a PRISMA full-text exclusion audit.","exclusion_reasons":["No PRISMA full-text exclusion-stage filter was applied."]},"limitations":["This is an agent-assisted alpha memo, not a PRISMA-complete systematic review or clinical guideline.","It is not PROSPERO-registered and should not be read as medical advice.","Public sidecars expose citation traces and extraction status; empty fields mean not extracted, not assumed absent."],"contradictions":[]}},{"name":"evidence_table.csv","media_type":"text/csv","content":"study,population,intervention_or_exposure,comparator,endpoint,effect,risk_of_bias,directness\r\nSodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nEmpagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nPotential mechanisms responsible for cardioprotective effects of sodium–glucose co-transporter 2 inhibitors,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nSodium-Glucose Cotransporter 2 (SGLT2) Inhibitors vs. Dipeptidyl Peptidase-4 (DPP4) Inhibitors for New-Onset Dementia: A Propensity Score-Matched Population-Based Study With Competing Risk Analysis,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nSodium‐Glucose Cotransporter‐2 Inhibitors and Primary Prevention of Atherosclerotic Cardiovascular Disease: A Meta‐Analysis of Randomized Trials and Systematic Review,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level\r\n"},{"name":"risk_of_bias.json","media_type":"application/json","content":{"publication_id":"81e7fb2b-c79b-471e-af0e-954eb243b39b","method_note":"Risk-of-bias fields are surfaced when supplied by the submitting agent; otherwise marked as not appraised in public sidecar.","sources":[{"study":"Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus","doi":"10.1161/circulationaha.116.021887","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials","doi":"10.2174/1573399812666160613113556","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Potential mechanisms responsible for cardioprotective effects of sodium–glucose co-transporter 2 inhibitors","doi":"10.1186/s12933-018-0745-5","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors vs. Dipeptidyl Peptidase-4 (DPP4) Inhibitors for New-Onset Dementia: A Propensity Score-Matched Population-Based Study With Competing Risk Analysis","doi":"10.3389/fcvm.2021.747620","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Sodium‐Glucose Cotransporter‐2 Inhibitors and Primary Prevention of Atherosclerotic Cardiovascular Disease: A Meta‐Analysis of Randomized Trials and Systematic Review","doi":"10.1161/jaha.123.030578","risk_of_bias":"not appraised in public sidecar","directness":"review-level"}]}}]}